Financial reports
10-Q
2024 Q1
Quarterly report
8 May 24
10-K
2023 FY
Annual report
14 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
10-K
2022 FY
Annual report
28 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
9 May 22
10-K
2021 FY
Annual report
1 Mar 22
Current reports
8-K
Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress
8 May 24
8-K
Changes in Registrant's Certifying Accountant
5 Apr 24
8-K
Regulation FD Disclosure
19 Mar 24
8-K/A
Results of Operations and Financial Condition
14 Mar 24
8-K
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
7 Mar 24
8-K
Departure of Directors or Certain Officers
23 Feb 24
8-K
Arcturus Therapeutics Announces Third Quarter 2023 Financial Update
14 Nov 23
8-K
Entry into a Material Definitive Agreement
26 Sep 23
8-K
Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese Government
14 Aug 23
8-K
Arcturus Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline Progress
7 Aug 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
7 Aug 23
S-3
Shelf registration
23 Dec 22
S-8
Registration of securities for employees
30 Jun 22
S-8
Registration of securities for employees
20 Oct 21
424B5
Prospectus supplement for primary offering
8 Dec 20
424B5
Prospectus supplement for primary offering
7 Dec 20
S-3ASR
Automatic shelf registration
7 Dec 20
S-8
Registration of securities for employees
5 Aug 20
S-8
Registration of securities for employees
5 Aug 20
424B5
Prospectus supplement for primary offering
30 Jul 20
Proxies
DEF 14A
Definitive proxy
29 Apr 24
DEF 14A
Definitive proxy
1 May 23
DEFR14A
Revised proxy
12 May 22
DEF 14A
Definitive proxy
2 May 22
DEF 14A
Definitive proxy
30 Apr 21
DEF 14A
Definitive proxy
13 Oct 20
PRE 14A
Preliminary proxy
2 Oct 20
DEF 14A
Definitive proxy
29 Apr 20
DEF 14A
Definitive proxy
1 Oct 19
Other
EFFECT
Notice of effectiveness
3 Jan 23
CORRESP
Correspondence with SEC
30 Dec 22
UPLOAD
Letter from SEC
29 Dec 22
EFFECT
Notice of effectiveness
8 Jul 20
CORRESP
Correspondence with SEC
19 Jun 20
EFFECT
Notice of effectiveness
22 May 20
CORRESP
Correspondence with SEC
18 May 20
UPLOAD
Letter from SEC
15 May 20
SEC STAFF
SEC staff action: Order
24 Feb 20
SEC STAFF
SEC staff action: Order
3 Feb 20
Ownership
SC 13G/A
BlackRock Inc.
5 Apr 24
4
Pad Chivukula
27 Mar 24
4
Pad Chivukula
21 Mar 24
144
Notice of proposed sale of securities
19 Mar 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
Nikko Asset Management Americas, Inc.
12 Feb 24
SC 13G/A
Sumitomo Mitsui Trust Holdings, Inc.
5 Feb 24
SC 13G/A
ARK Investment Management LLC
29 Jan 24
SC 13G/A
BlackRock Inc.
25 Jan 24
SC 13G/A
STATE STREET CORP
25 Jan 24